BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin C, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions. Clin Pharmacokinet 2020;59:781-808. [DOI: 10.1007/s40262-019-00856-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network. Pharmaceutics 2021;13:331. [PMID: 33806634 DOI: 10.3390/pharmaceutics13030331] [Reference Citation Analysis]
2 Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol 2020;76:833-42. [PMID: 32157329 DOI: 10.1007/s00228-020-02841-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Y, Zhao S, Wang C, Zhou P, Zhai S. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization. Front Pharmacol 2021;12:636097. [PMID: 33815119 DOI: 10.3389/fphar.2021.636097] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shibata Y, Tamemoto Y, Singh SP, Yoshitomo A, Hozuki S, Sato H, Hisaka A. Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Drug Metab Pharmacokinet 2021;39:100396. [PMID: 33992954 DOI: 10.1016/j.dmpk.2021.100396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 2021. [PMID: 34751931 DOI: 10.1007/s12272-021-01357-z] [Reference Citation Analysis]
6 Fisher MC, Alastruey-izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, Bromley M, Brüggemann R, Garber G, Cornely OA, Gurr SJ, Harrison TS, Kuijper E, Rhodes J, Sheppard DC, Warris A, White PL, Xu J, Zwaan B, Verweij PE. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. [DOI: 10.1038/s41579-022-00720-1] [Reference Citation Analysis]
7 Chen L, Li L, Chen W. Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib. Clin Pharmacol Drug Dev 2022. [PMID: 34995400 DOI: 10.1002/cpdd.1049] [Reference Citation Analysis]
8 Kulkarni PR, Youssef AS, Argikar AA. Prediction of Drug Clearance from Enzyme and Transporter Kinetics. Methods Mol Biol 2021;2342:369-417. [PMID: 34272702 DOI: 10.1007/978-1-0716-1554-6_14] [Reference Citation Analysis]
9 Chen C, Xu T, Zhou K, Zhu S. Factors affecting voriconazole concentration to dose ratio changes according to route of administration. Eur J Hosp Pharm 2022:ejhpharm-2021-003173. [PMID: 35273002 DOI: 10.1136/ejhpharm-2021-003173] [Reference Citation Analysis]
10 Wiebe ST, Meid AD, Mikus G. Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity. J Pharmacokinet Pharmacodyn 2020;47:527-42. [PMID: 32772302 DOI: 10.1007/s10928-020-09704-1] [Reference Citation Analysis]
11 Stader F, Battegay M, Marzolini C. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir. Clin Pharmacol Ther 2021;110:1231-9. [PMID: 33626178 DOI: 10.1002/cpt.2221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Li X, Junge L, Taubert M, von Georg A, Dahlinger D, Starke C, Frechen S, Stelzer C, Kinzig M, Sörgel F, Jaehde U, Töx U, Goeser T, Fuhr U. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. J Clin Pharmacol 2020;60:1237-53. [PMID: 32427354 DOI: 10.1002/jcph.1619] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T, Miyamoto T, Egashira N, Akashi K, Ieiri I. Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Drugs R D 2021;21:419-29. [PMID: 34655050 DOI: 10.1007/s40268-021-00365-0] [Reference Citation Analysis]